Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 16, 2020 07:30 ET | Source: Harpoon Therapeutics

Harpoon Therapeutics to Participate in the 32nd Annual Piper Sandler Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
November 12, 2020 16:15 ET | Source: Harpoon Therapeutics

Harpoon Therapeutics Presents Encouraging Preclinical Data for HPN601 EpCAM ProTriTAC™ Program at 35th SITC Annual Meeting

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today presented...
November 09, 2020 07:30 ET | Source: Harpoon Therapeutics

Harpoon Therapeutics to Participate in Two Upcoming Virtual Conferences

SOUTH SAN FRANCISCO, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
November 05, 2020 07:30 ET | Source: Harpoon Therapeutics

Harpoon Therapeutics Abstract for HPN601 EpCAM ProTriTAC™ Program Accepted for Oral Presentation at Upcoming 35th SITC Annual Meeting

SOUTH SAN FRANCISCO, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, announced today...
November 04, 2020 16:05 ET | Source: Harpoon Therapeutics

Harpoon Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
November 03, 2020 07:30 ET | Source: Harpoon Therapeutics

Harpoon Therapeutics Appoints Omer Siddiqui as VP Development Operations and Project Management

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
September 09, 2020 16:05 ET | Source: Harpoon Therapeutics

Harpoon Therapeutics to Participate in the Cantor Virtual Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
September 02, 2020 07:30 ET | Source: Harpoon Therapeutics

Harpoon Therapeutics to Participate in Two Upcoming Virtual Conferences

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
August 26, 2020 07:30 ET | Source: Harpoon Therapeutics

Harpoon Therapeutics Names Karin Ann Thacker, M.Sc., VP Regulatory Affairs and Quality Assurance

SOUTH SAN FRANCISCO, Calif., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
August 05, 2020 16:05 ET | Source: Harpoon Therapeutics

Harpoon Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update

Presented positive interim Phase 1 clinical trial data for PSMA-targeting HPN424 in prostate cancer at ASCO20, supporting increased dose escalation Dosed first patient with HPN217 targeting BCMA for...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right